These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39032872)

  • 1. Development of a screening platform for the formulation of poorly water-soluble drugs as albumin-stabilized nanosuspensions using nab™ technology.
    Adick A; Hoheisel W; Schneid S; Hester S; Langer K
    Int J Pharm; 2024 Sep; 662():124491. PubMed ID: 39032872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.
    Adick A; Hoheisel W; Schneid S; Mulac D; Azhdari S; Langer K
    Eur J Pharm Biopharm; 2023 Dec; 193():129-143. PubMed ID: 37918678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spray drying of API nanosuspensions: Importance of drying temperature, type and content of matrix former and particle size for successful formulation and process development.
    Czyz S; Wewers M; Finke JH; Kwade A; van Eerdenbrugh B; Juhnke M; Bunjes H
    Eur J Pharm Biopharm; 2020 Jul; 152():63-71. PubMed ID: 32376369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and drying of miconazole and itraconazole nanosuspensions.
    Cerdeira AM; Mazzotti M; Gander B
    Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of nanosuspensions into dry powders by spray drying: a case study.
    Chaubal MV; Popescu C
    Pharm Res; 2008 Oct; 25(10):2302-8. PubMed ID: 18509597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate.
    Ma Y; Cong Z; Gao P; Wang Y
    Eur J Pharm Sci; 2023 Jun; 185():106425. PubMed ID: 36934992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation aspects of intravenous nanosuspensions.
    Patel D; Zode SS; Bansal AK
    Int J Pharm; 2020 Aug; 586():119555. PubMed ID: 32562654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions.
    Oktay AN; Ilbasmis-Tamer S; Celebi N
    Pharm Dev Technol; 2019 Dec; 24(10):1278-1286. PubMed ID: 31535942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components studied by a mixture design.
    Foglio Bonda A; Rinaldi M; Segale L; Palugan L; Cerea M; Vecchio C; Pattarino F
    Eur J Pharm Sci; 2016 Feb; 83():175-83. PubMed ID: 26742430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
    Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
    Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
    Merisko-Liversidge E; Liversidge GG
    Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of an orodispersible film containing drug nanoparticles.
    Shen BD; Shen CY; Yuan XD; Bai JX; Lv QY; Xu H; Dai L; Yu C; Han J; Yuan HL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1348-56. PubMed ID: 24103635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
    Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
    Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of multiparticulate systems for oral delivery of a micronized or nanosized poorly soluble drug.
    Cerea M; Pattarino F; Foglio Bonda A; Palugan L; Segale L; Vecchio C
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1466-75. PubMed ID: 26786555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery.
    Wang Z; Li Z; Zhang D; Miao L; Huang G
    Drug Deliv; 2015 Jan; 22(1):79-85. PubMed ID: 24401038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.